Literature DB >> 3490639

Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults.

M Gupta, B K Gupta, R Thomas, V Bruemmer, J R Sladek, D L Felten.   

Abstract

Parkinson's disease is a neurodegenerative disorder characterized mainly by damage to the dopaminergic nigrostriatal system. Recently, the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown to induce damage in the nigrostriatal system, accompanied by Parkinson-like symptoms in humans. We present here evidence that MPTP treatment in aged 21-month-old mice produced a marked reduction in the presence and intensity of fluorescence in noradrenergic neurons of the locus coeruleus and in dopaminergic neurons of the ventral tegmental area in addition to extensive damage to the substantia nigra. Aged mice treated with MPTP also showed physical signs of movement disability characterized by marked akinesia, rigidity of the hind limbs, and an initial resting tremor of the entire body. Such symptoms were less evident in young mice treated with MPTP. These remarkable initial behavioral effects of MPTP treatment in aged mice and evidence of reduced catecholamine fluorescence in the locus coeruleus and ventral tegmental area suggest that aged mice are more sensitive to, and more severely affected by MPTP treatment than young mice. We suggest that these MPTP-treated aged mice provide a useful animal model for studying both anatomical and functional characteristics of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490639     DOI: 10.1016/0304-3940(86)90573-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

Review 1.  Current theories on the cause of Parkinson's disease.

Authors:  J W Langston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

2.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

4.  Modifications of precentral cortex discharge and EMG activity in monkeys with MPTP-induced lesions of DA nigral neurons.

Authors:  D J Doudet; C Gross; M Arluison; B Bioulac
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

Review 5.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 6.  Behavioral phenotyping of mouse models of Parkinson's disease.

Authors:  Tonya N Taylor; James G Greene; Gary W Miller
Journal:  Behav Brain Res       Date:  2010-03-06       Impact factor: 3.332

7.  MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN).

Authors:  A Fredriksson; P Eriksson; T Archer
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

8.  Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice.

Authors:  M Gupta; H L Wiener
Journal:  Neurochem Res       Date:  1995-04       Impact factor: 3.996

9.  Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system.

Authors:  D E Dluzen; J L McDermott; L I Anderson
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

10.  CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.

Authors:  Fabrine Sales Massafera Tristão; Márcio Lazzarini; Sabine Martin; Majid Amar; Walter Stühmer; Frank Kirchhoff; Lucas Araújo Caldi Gomes; Laurance Lanfumey; Rui D Prediger; Julia E Sepulveda; Elaine A Del-Bel; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2015-09-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.